Brown, Lisle/Cummings, Inc. Amarin Corp Plcuk Transaction History
Brown, Lisle/Cummings, Inc.
- $307 Billion
- Q2 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Amarin Corp Plcuk stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 725 shares of AMRN stock, worth $442. This represents 0.0% of its overall portfolio holdings.
Number of Shares
725Holding current value
$442% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AMRN
# of Institutions
187Shares Held
77.1MCall Options Held
247KPut Options Held
121K-
Sarissa Capital Management LP Greenwich, CT24.9MShares$15.2 Million2.89% of portfolio
-
Kynam Capital Management, LP Princeton, NJ12.2MShares$7.42 Million0.65% of portfolio
-
Dg Capital Management, LLC New York, NY5.12MShares$3.12 Million1.36% of portfolio
-
Eversept Partners, LP New York, NY4.31MShares$2.63 Million0.22% of portfolio
-
Two Sigma Investments, LP New York, NY3.04MShares$1.85 Million0.01% of portfolio
About AMARIN CORP PLCUK
- Ticker AMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 403,206,016
- Market Cap $246M
- Description
- Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...